Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma
Original Article
T.K. Choueiri, T. Powles, K. Peltola, G.d. Velasco, M. Burotto, C. Suarez, P. Ghatalia, R. Iacovelli, E.T. Lam, E. Verzoni, M. Gümüş, W.M. Stadler, C. Kollmannsberger, B. Melichar, B. Venugopal, M. Gross-Goupil, A. Poprach, M.D. Santis, F.A. Schutz, S.H. Park, D.A. Nosov, C. Porta, J.L. Lee, X. Garcia-del-Muro, E. Biscaldi, R.M. Kopp, M. Oya, L. He, A. Wang, R.F. Perini, D. Vickery, L. Albiges, and B. Rini
N Engl J Med 2024;391:710-721
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Please sign in or create an account to take the course.